HER2-positive breast cancer with brain metastasis: long-lasting response after lapatinib treatment

Carcinoma mammario HER2-positivo con metastasi cerebrali: risposta prolungata dopo trattamento con lapatinib

Abstract

We report the case of a 50-year-old patient diagnosed with breast cancer with lymph node, lymph node, pulmonary and hepatic secondaryisms. After receiving a first line chemotherapy containing taxanes, pertuzumab and trastuzumab, the patient developed asymptomatic brain metastases. She is therefore treated with panencephalic radiotherapy and second line treatment with trastuzumab emtansine. Further to systemic and cerebral disease progression, the patient is treated with capecitabine and lapatinib. This treatment lasted approximately 6 months with sustained efficacy on secondary lesions and an excellent tolerance profile (Oncology)